Japan Tobacco Inc.

Fujikura Limited

Wataru Kondo

Masahiro Sakata

Shinji Yata

Yoshikazu Hori

Takayuki Yamasaki

Yoshihisa Koga

Takuya Matsuo

Yasuyuki Tachikawa

Yoshinori Sano

Takashi Watanabe

Makoto Takamatsu

Shinsuke Aoshima

Yohei Kurikawa

Tatsuya Matsumoto

Osamu Aoki

Toshimizu Tomitsuka

Yasushi Ono

Hidekazu Ozeki

An input device includes an insulation substrate, a switch element, and a detection portion. The switch element includes a fixed electrode portion that is provided on the substrate, and a movable electrode portion that is provided on a main surface side of the substrate, at least part of the movable electrode portion being elastically displaceable toward a direction approaching and leaving the fixed electrode portion. The movable electrode portion is displaceable toward a direction approaching the fixed electrode portion due to pressure from an object to be detected that is an electric conductor. The detection portion is capable of detecting a capacitance change caused by the object to be detected approaching and leaving the movable electrode portion and a capacitance change between the movable electrode portion and the fixed electrode portion produced by displacement of the movable electrode portion due to pressing.

Input device

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt: 

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR; Ris a hydrogen atom or a halogen atom; Ris a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and Ris a halogen atom. However, Ris a halogen atom when X is CR). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc. 

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

Growing community of inventors

Takatsuki, Japan

Wataru Kondo